Limfomiozot drops 30 ml.


Manufacturer: Germany

In the treatment of lymphadenitis, a lymphangitis, limfatice; postoperative and post-traumatic edema; allergic disease; consequences of long-term action of endo-and exotoxins (physical factors, chemical agents, biological factors, including tonsillogenic and tuberculosis intoxication).



Composition active ingredients Limfomiozot

100 g of the preparation contain: Araneus diadematus D6 – 5 g, Calcium phosphoricum D12 – 5 g, Equisetum hiemale D4 – 5 g, Ferrum iodatum D12 – 10 g, Fumaria officinalis D4 – 5 g, Gentiana lutea D5 – 5 g, Geranium robertianum D4 – 10 g, Juglans regia ssp. regia D3 – 5 g, Levothyroxinum D12 – 5 g, Myosotis arvensis D3 – 5 g, Nasturtium officinale D4 – 10 g, Natrium sulfuricum D4 – 5 g, Pinus sylvestris D4 – 5 g, Scrophularia nodosa D3 – 5 g, Smilax D6 – 5 g, Teucrium scorodonia D3 5 g, Veronica officinalis D3 5 g; excipients: ethanol 96%, purified water. The drug contains 35% vol. ethanol 96%. 1 ml of the drug Limfomiozot contains 21 drops.

Dosage form

Oral Limfomiozot drops.

Dain physical and chemical properties:

transparent, slightly light yellow to light yellow solution with an ethanol odor.

Pharmacological group

Complex homeopathic preparation.

Pharmacological properties

Pharmacological. The drug Limfomiozot improves the outflow of lymph from all organs and tissues, has a detoxifying, anti-exudative, immunocorbing, anti-inflammatory effect, which is based on activating the body’s defenses and normalizing impaired functions due to substances of plant, mineral and animal origin that are part of the drug. Indications As part of the complex therapy of lymphadenitis, lymphangitis, lymph edema; postoperative and post-traumatic edema, allergic diseases, as well as the consequences of long-term action of various toxic factors: endo and exotoxins (physical factors, chemical agents, biological factors, including tonsillogenic and tuberculous intoxication). Contraindications Hypersensitivity to the components of the drug Limfomiozot.

Interaction with other drugs and other kinds of interactions

The drug Limfomiozot is compatible with other drugs.

Features of application

Do not use Limfomiozot for thyroid diseases without consulting a doctor. If symptoms persist or the patient’s condition worsens, consult a doctor.

Application during pregnancy or breastfeeding

The question of the advisability of using the drug for pregnant and lactating women is decided by the doctor individually, taking into account the benefits / risks.

Ability to influence the rate of response when driving motor vehicles or other mechanisms

Exposure is unknown. Dosage and administration Single dose Limfomiozot for adults and children over 12 years old – 10 drops, children under 1 year old – 1-2 drops, children aged 1 to 3 years old – 3 drops, children aged 3 to 6 years old – 5 drops , children from 6 to 12 years old – 7 drops 3 times a day 15-20 minutes before meals or 1:00 after meals. Dissolve the drops in 10 ml of water and drink, holding in the mouth for a few seconds. In acute cases, a single age dose of Limfomiozot should be taken every 15-30 minutes during the first 2-3 hours, but no more than 8-10 times. Then go to the reception 3 times a day. In case of hyperthyroidism, taking the drug should be started with ½ a single age dose, increasing daily or every other day by 1-2 drops, bringing it to a single age dose. The duration of the course of treatment and the frequency of admission are determined by the doctor depending on the nature and course of the disease. Typically, the course of treatment for Limfomiozot is 2-5 weeks.


The drug Limfomiozot is recommended for use in children from birth. Overdose Not observed. Adverse reactions In very rare cases, hypersensitivity reactions are possible, including rash, itching, urticaria.

Shelf life

5 years.

Storage conditions

Store Limfomiozot in its original packaging at a temperature not exceeding 25 ° C out of reach of children.


The cardboard box contains a glass dropper bottle of 30 ml.

Holiday category

No prescription. More details: